Abiad May, Zargarzadeh Nikan, Javinani Ali, Krispin Eyal, Shamshirsaz Alireza A
Fetal Care and Surgery Center (FCSC), Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Clin Med. 2024 Oct 19;13(20):6245. doi: 10.3390/jcm13206245.
Fetal teratomas, though rare, represent a significant proportion of tumors arising during fetal development. These tumors arise from pluripotent cells and can present in varying degrees of severity, ranging from incidental findings to life-threatening conditions. Prenatal imaging, via ultrasound and MRI, is necessary for diagnosis and risk assessment. The management of fetal teratomas, particularly those associated with complications like hydrops or airway obstruction, often requires a multidisciplinary approach. Interventions such as ex-utero intrapartum treatment (EXIT) procedures and minimally invasive alternatives have emerged as critical tools to improve neonatal outcomes in severe cases. Despite advances in fetal therapies, careful prenatal monitoring and individualized management remain essential, especially for tumors with high vascularity or those that risk compromising cardiac output. This review explores the diagnostic methods, management strategies, and outcomes associated with fetal teratomas, highlighting recent advancements that contribute to improving survival and reducing morbidity in affected neonates.
胎儿畸胎瘤虽然罕见,但在胎儿发育过程中产生的肿瘤中占相当大的比例。这些肿瘤起源于多能细胞,严重程度各不相同,从偶然发现到危及生命的情况都有。通过超声和磁共振成像(MRI)进行产前成像对于诊断和风险评估是必要的。胎儿畸胎瘤的治疗,尤其是那些与水肿或气道阻塞等并发症相关的畸胎瘤,通常需要多学科方法。诸如产时宫外治疗(EXIT)程序和微创替代方法等干预措施已成为改善严重病例新生儿结局的关键工具。尽管胎儿治疗取得了进展,但仔细的产前监测和个体化管理仍然至关重要,特别是对于血管丰富或有影响心输出量风险的肿瘤。本综述探讨了与胎儿畸胎瘤相关的诊断方法、管理策略和结局,强调了有助于提高受影响新生儿生存率和降低发病率的最新进展。